Thanos Tsaktanis

Erlangen, BY, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study.

Hospital resource use and costs in autoimmune encephalitis: a single-center retrospective cohort study.

Journal: Neurological research and practice
Published: January 13, 2026

Complement C4d Informs the Differential Diagnosis of Inflammatory Demyelinating CNS Diseases.

Complement C4d Informs the Differential Diagnosis of Inflammatory Demyelinating CNS Diseases.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: December 23, 2025

Interferon-β and FTY720 ameliorate progressive CNS inflammation via SOCS1-associated astrocyte signaling.

Interferon-β and FTY720 ameliorate progressive CNS inflammation via SOCS1-associated astrocyte signaling.

Journal: Scientific reports
Published: November 27, 2025

Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity.

Serum Levels of Aryl Hydrocarbon Receptor Plasma Agonist Activity Are Reduced in Patients With NMOSD and Correlate With Disease Activity.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: August 05, 2025

Artificial Intelligence analysis of lesion dynamics and brain volume in patients with multiple sclerosis.

Artificial Intelligence analysis of lesion dynamics and brain volume in patients with multiple sclerosis.

Journal: Multiple sclerosis and related disorders
Published: July 20, 2025

Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis: A Multicenter Cohort Study.

Comorbidities and Their Influence on Outcomes and Infectious Complications in Autoimmune Encephalitis: A Multicenter Cohort Study.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: July 07, 2025

Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer's disease.

Reduced serum AHR agonistic activity reflects amyloid dysregulation in AT1 subtypes of Alzheimer's disease.

Journal: Alzheimer's research & therapy
Published: June 11, 2025

Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study.

Metabolomic and immunophenotypic signatures in cerebral amyloid angiopathy: a pilot study.

Journal: Scientific reports
Published: May 15, 2025

Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristics.

Recruitment of the multiple sclerosis cohort within the European Mobilise-D clinical validation study-lessons learnt, baseline demographics and clinical characteristics.

Journal: Trials
Published: February 24, 2025

Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis.

Modulator of VRAC Current 1 Is a Potential Target Antigen in Multiple Sclerosis.

Journal: Neurology(R) neuroimmunology & neuroinflammation
Published: February 11, 2025

Case report: Cerebrospinal fluid neutrophilic pleocytosis upon intrathecal triamcinolone injection.

Case report: Cerebrospinal fluid neutrophilic pleocytosis upon intrathecal triamcinolone injection.

Journal: Frontiers in neurology
Published: January 17, 2024

Successful Pharmacologic Treatment of Self-Bloodletting with Factitious Chronic Anemia (Lasthénie de Ferjol Syndrome) with High-Dose Serotonergic Medication: A Case Report.

Successful Pharmacologic Treatment of Self-Bloodletting with Factitious Chronic Anemia (Lasthénie de Ferjol Syndrome) with High-Dose Serotonergic Medication: A Case Report.

Journal: Behavioral sciences (Basel, Switzerland)
Published: January 11, 2024
Showing 1-12 of 24

Last Updated: 09/26/2026